Intetumumab
Intetumumab Basic information
- Product Name:
- Intetumumab
- Synonyms:
-
- Intetumumab
- Research Grade Intetumumab(DHC21903)
- Research Grade Intetumumab
- Intetumumab (anti-ITGAV)
- CAS:
- 725735-28-4
- MW:
- 0
- Mol File:
- Mol File
Intetumumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Intetumumab Usage And Synthesis
Uses
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2].
in vivo
Intetumumab (CNTO 95; 10 mg/kg; i.p.; Male nude rats) inhibits tumor growth and inhibits spontaneous lung metastasis of A549 tumors and decreases both the number of rats with lung metastasis and the number of metastatic lesions per lung[2].
| Animal Model: | Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)[2] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; once a week for 60 days |
| Result: | Had the total tumor response rates (CR and PR) was 33% in A549 tumor model. Developed lung metastases only 4 of 9 rats. |
References
[1] Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90. DOI:10.1097/IGC.0b013e3182187324
[2] Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61. DOI:10.1158/1078-0432.CCR-14-2579
IntetumumabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com